TKNO Q1 2022 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q1 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$11M+22.8% YoY

Gross Profit

$5M48.0% margin

Operating Income

-$6M-52.4% margin

Net Income

-$5M-49.3% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+10.3%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$11M

Stock-Based Comp.

$787,000

Balance Sheet

Total Assets

$184M

Total Liabilities

$46M

Stockholders' Equity

$139M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$9M	+22.8%
Gross Profit	$5M	$5M	+6.4%
Operating Income	-$6M	-$828,000	-605.7%
Net Income	-$5M	-$655,000	-739.2%

Revenue Segments

Lab Essentials

$7M63%

Clinical Solutions

$4M34%

Other Product

$354,0003%

Sample Transport

$6,0000%

Geographic Segments

UNITED STATES

$11M97%

Non-US

$327,0003%